Systemic Lupus Erythematosus Decrease

PHILADELPHIA — Half of patients with systemic lupus erythematosus and new-onset, low-grade proteinuria progress to clinical proteinuria within 2 years, according to results of a study presented at ACR Convergence 2022.

SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.

Patients with systemic lupus erythematosus who achieve remission, regardless of treatment status, or low disease activity are less likely to accrue as much systematic damage as those who do not reach treatment goals, according to data.

Although commonly referred to as an “invisible illness,” lupus — and some of its treatments — can manifest in ways that are not only visible, but also heavily impact the daily lives of patients.

DESTIN, Fla. — Systemic lupus erythematosus may benefit from being redefined and further subdivided, depending on the autoantibody profile of the patient, according to a speaker at the Congress of Clinical Rheumatology East 2022.

Neuropsychiatric events caused by systemic lupus erythematosus are associated with active disease, male sex, corticosteroids and concurrent non-lupus events, except headaches, according to data published in Arthritis & Rheumatology.

Systemic lupus erythematosus is 2.3 times more prevalent among patients with psoriatic arthritis compared with the general population, according to data published in The Journal of Rheumatology.

Anifrolumab is superior to placebo for improved BILAG-2004 and SLEDAI-2K domain scores, as well as in mucocutaneous and musculoskeletal domains, among patients with systemic lupus erythematosus, according to a speaker at ACR Convergence.